Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials

Purpose: Sorafenib is the only approved drug in first-line treatment for hepatocellular carcinoma. Recently, the Phase III REFLECT trial proved lenvatinib not inferior to sorafenib, potentially establishing a new standard of care in this setting. The study showed that both have similar overall survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Casadei Gardini, Andrea, Puzzoni, Marco, Montagnani, Francesco, Marisi, Giorgia, Tamburini, Emiliano, Cucchetti, Alessandro, Solaini, Leonardo, Foschi, Francesco Giuseppe, Conti, Fabio, Ercolani, Giorgio, Cascinu, Stefano, Scartozzi, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499482/
https://www.ncbi.nlm.nih.gov/pubmed/31118665
http://dx.doi.org/10.2147/OTT.S192572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499482/
https://www.ncbi.nlm.nih.gov/pubmed/31118665
http://dx.doi.org/10.2147/OTT.S192572

Ejemplares similares